title: Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results.
abstract: OBJECTIVE
  To analyze the 10-year results of corneal collagen crosslinking (CXL) for keratoconus.
  
  
  METHODS
  Department of Ophthalmology, University Hospital, Dresden, Germany.
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  The study included eyes treated for progressive keratoconus from 2000 to 2004. Corneal collagen crosslinking was performed by applying riboflavin and ultraviolet-A. The corrected distance visual acuity (CDVA), corneal topography, and endothelial cell count (ECC) were recorded preoperatively and 10 years postoperatively.
  
  
  RESULTS
  The study enrolled 24 patients (34 eyes). The mean age of the 18 men and 6 women was 28.4 years ± 7.3 (SD) and the mean follow-up, 131.9 ± 20.1 months. The mean apical keratometry (K) value was 61.5 diopters (D) preoperatively and 55.3 D 10 years postoperatively; the decrease was statistically significant (P<.001). The mean values for maximum K (53.2 D and 49.56 D, respectively) and minimum K (47.5 D and 45.5 D, respectively) were also significantly lower (P<.001). The preoperative and postoperative CDVA were statistically significantly different (P=.002). The mean CDVA improved by 0.14 logMAR over preoperatively; the change was statistically significant (P=.002). The ECC was unchanged.
  
  
  CONCLUSIONS
  Corneal CXL was effective in treating progressive keratoconus, achieving long-term stabilization of the condition. It was easy to perform, had a good safety profile, and reduced the need for corneal transplantation.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the Department of Ophthalmology (Raiskup, Theuring, Pillunat, Spoerl), C.G. Carus University Hospital, Dresden, Germany; the Department of Ophthalmology (Raiskup), Faculty of Medicine Hradec Králové, Charles University, Prague, Czech Republic. Electronic address: frederik.raiskup@uniklinikum-dresden.de.
authors.forename: Frederik
authors.initials: F
authors.lastname: Raiskup
authors.affiliation: From the Department of Ophthalmology (Raiskup, Theuring, Pillunat, Spoerl), C.G. Carus University Hospital, Dresden, Germany; the Department of Ophthalmology (Raiskup), Faculty of Medicine Hradec Králové, Charles University, Prague, Czech Republic.
authors.forename: Anja
authors.initials: A
authors.lastname: Theuring
authors.affiliation: From the Department of Ophthalmology (Raiskup, Theuring, Pillunat, Spoerl), C.G. Carus University Hospital, Dresden, Germany; the Department of Ophthalmology (Raiskup), Faculty of Medicine Hradec Králové, Charles University, Prague, Czech Republic.
authors.forename: Lutz E
authors.initials: LE
authors.lastname: Pillunat
authors.affiliation: From the Department of Ophthalmology (Raiskup, Theuring, Pillunat, Spoerl), C.G. Carus University Hospital, Dresden, Germany; the Department of Ophthalmology (Raiskup), Faculty of Medicine Hradec Králové, Charles University, Prague, Czech Republic.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Spoerl
mesh_terms: D000293:Adolescent; D000328:Adult; D003094:Collagen / Q000378:metabolism*; D003319:Corneal Stroma / Q000378:metabolism*; D003432:Cross-Linking Reagents; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012256:Riboflavin / Q000009:adverse effects / Q000627:therapeutic use*; D014466:Ultraviolet Rays; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin